DOCSLIB.ORG

The Relaxation Effect and Mechanism of Action of Higenamine in the Rat Corpus Cavernosum

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Relaxation Effect and Mechanism of Action of Higenamine in the Rat Corpus Cavernosum International Journal of Impotence Research (2012) 24, 77–83 & 2012 Macmillan Publishers Limited All rights reserved 0955-9930/12 www.nature.com/ijir ORIGINAL ARTICLE The relaxation effect and mechanism of action of higenamine in the rat corpus cavernosum SC Kam1,JMDo1, JH Choi1, BT Jeon2, GS Roh2, KC Chang3 and JS Hyun1 1Department of Urology, Institute of Health Sciences, Gyeongsang National University School of Medicine, Jinju, Korea; 2Department of Anatomy, Institute of Health Sciences, Gyeongsang National University School of Medicine, Jinju, Korea and 3Department of Pharmacology, Institute of Health Sciences, Gyeongsang National University School of Medicine, Jinju, Korea Higenamine mediates cardiotonic, vascular relaxation and bronchodilator effects. The relaxation effects and the mechanism of action of higenamine on the rat corpus cavernosum (CC) were assessed to investigate the effect of higenamine on penile erection. Strips of CC and aorta were used in organ baths for isometric tension studies. Tension was measured with isometric force transducers, and muscle relaxation was expressed as the percent decrease in precontraction induced by phenylephrine (PE). The relaxation reactions were investigated in an endothelial-denuded group and groups pretreated with N(G)-nitro-L-arginine methyl ester (NO synthesis inhibitor), þ propranolol (b-receptor blocker), indomethacin (COX inhibitor), glibenclamide (KATP channel inhibitor), 4-aminopyridine (membrane potential-dependent potassium channel inhibitor) and methylene blue (guanylyl cyclase inhibitor) for 30 min. Intracavernous pressure (ICP) was assessed in rats after the intravenous administration of higenamine, and changes in guanosine 30,50-cyclic monophosphate and adenosine 30,50-cyclic monophosphate (cAMP) concentrations were measured on the basis of the higenamine concentration. Also, the combined reaction of higenamine and the phosphodiesterase type-5 (PDE-5) inhibitors was assessed. Higenamine induced relaxation of the CC and the aortic strips precontracted with PE in a dose-dependent manner. The CC was significantly more relaxed than the aortic rings in response to the same higenamine concentration (Po0.05). The CC relaxation reaction was suppressed by the b-receptor blocker propranolol. The cAMP concentration increased gradually with increased higenamine concentration (Po0.05). The ICP also increased with increased higenamine concentration in vivo (Po0.05). In the group pretreated À7 with 10 M higenamine, the relaxation reaction of CC induced by the PDE-5 inhibitor increased significantly, compared with CC exposed to the PDE-5 inhibitor but not pretreated with higenamine (Po0.05). In conclusion, higenamine induced relaxation of the rat CC in a dose-dependent manner. The effect may be mediated through b-adrenoceptors. The results suggest that higenamine may be valuable as a new lead compound for treating erectile dysfunction. International Journal of Impotence Research (2012) 24, 77–83; doi:10.1038/ijir.2011.48; published online 29 September 2011 Keywords: corpus cavernosum; erection; higenamine Introduction important previously have appeared. Among them, male erectile dysfunction (ED) is a disease that With the development of medicines and improve- greatly affects the quality of life. ments in general hygiene, the average lifespan The incidence of ED in males older than 40 is 52% has been prolonged and several problems concern- according to the Massachusetts Male Study.1 ing the quality of life that were not considered Additionally, the incidence of ED increases with age. That is, many males past middle age have ED. Recently developed phosphodiesterase type-5 (PDE-5) inhibitors have been widely used as first- Correspondence: Dr J-S Hyun, Department of Urology, line therapeutics for treating ED. Although large Institute of Health Sciences, Gyeongsang National Uni- multicenter clinical trials have shown the efficacy versity School of Medicine, 90 Chilamdong, Jinju 660-702, South Korea. and tolerability of these drugs in ED with various E-mail: [email protected] etiologies and a broad range of severity, 30–35% of Received 12 January 2011; revised 5 July 2011; accepted patients fail to respond. The reported 62% prescrip- 17 August 2011; published online 29 September 2011 tion renewal rate at 3-4 months of follow-up, which Mechanism of action of higenamine on penile erection SC Kam et al 78 drops to approximately 30% by 6-12 months, condition was restored by washing the preparation suggests that patients stop taking the drug for with KH solution three more times. Such mani- reasons other than treatment failure.2,3 The use of pulation was repeated, and contracture within PDE-5 inhibitors may result in side effects, such as 100±10% of the previous contraction was defined visual disturbance, headache, facial flushing, rhini- as the ideal resting optimal isometric tension. tis and indigestion. Other treatments for ED include Although maintaining the resting optimal isometric injection therapy within the penis or penile tension, tissues were contracted by pretreatment À6 implants. However, such methods are invasive and with PE (5 Â 10 M) within the bath, higenamine in 4 À7 À5 irreversible, and have not been used widely. Thus, five-fold dilutions from 10 to 10 M was added, there is a continuing need for the development and the relaxation level was assessed by observing of new non-invasive and effective therapies for the change in the tension curve. patients with ED. The relaxation reactions were investigated in Kosuge et al.5 purified a substance from the endothelial-intact or endothelial-denuded groups perennial Aconiti tuber plant belonging to to examine the mechanism of higenamine-induced Ranunculaceae, which has an active cardiotonic relaxation of the CC. Endothelial-intact or -denuded component, characterized its chemical structure, tissues from the CC were incubated for 30 min in KH and named it ‘higenamine.’ Higenamine mediates solution containing various drugs. After incubation, 5,6 7 8 À6 cardiotonic, vascular relaxation, bronchodilator the tissues were contracted with PE (5 Â 10 M), and anti-thrombotic effects,9,10 and reduces apopto- during which period the plateau state contraction tic cell death in vivo,11 suggesting that higenamine was attained. The relaxation reaction following the has various actions on the cardiovascular system addition of increasing concentrations of higenamine and that it may have an effect on penile erection. was then observed. Drug probes included N(G)- À5 In this study, we investigated the effect of nitro-L-arginine methyl ester (L-NAME; 10 M,NO À5 higenamine on relaxation of the corpus cavernosum synthesis inhibitor), propranolol (10 M, b-receptor À5 (CC) in rats. The mutual action of higenamine and blocker), indomethacin (3 Â 10 M, COX inhibitor), À5 þ PDE-5 inhibitors was also assessed. glibenclamide (10 M,KATP channel inhibitor), À5 4-aminopyridine (10 M, membrane potential- dependent potassium channel inhibitor) and methy- À5 12–14 lene blue (10 M, guanyl cyclase inhibitor). Materials and methods Eight sections were used for each group. CC sections were pretreated with 3 ml 0.3% 3-[(3-cholamide Organ-bath study of the CC propyl)]-1-propane sulfonate (CHAPS) for 20 s to We sectioned the CC of male Sprague Dawley rats, remove vascular endothelial cells. The sections 9–11 weeks old, weighing 280–320 g; eight animals were rubbed lightly using the thumb and index per group were used. The rats were killed by finger for 20 s, washed with KH solution, and the cervical dislocation, the penis was dissected cells were removed by rolling gently on dry paper. immediately, and 2 Â 2 Â 6-mm sections of the CC The removal of vascular endothelial cells was were prepared. The thoracic aorta was extracted, confirmed by the failure of the loss of tissue À5 connective tissues were removed, and aortic rings of contraction induced by acetylcholine (10 M)in À6 3 mm in length were prepared. CC sections and response to PE (5 Â 10 M). aortic rings were transferred to an organ bath; one end was connected to a muscle fixation ring and the other end was connected to an isometric tension transducer (SG-10). The signals were relayed to a Measurement of guanosine 30,50-cyclic physiography instrument (PowerLab ADI Instru- monophosphate (cGMP) and adenosine 30,50-cyclic ments, Sydney, Australia) and measured. Chart 5 monophosphate (cAMP) in the rat CC software (ADI Instruments) was used for real-time Contraction of the smooth muscle sections was monitoring of tension. Krebs–Hanseleit (KH) solu- equalized for 1 h in KH solution, induced with tion was used for the organ bath at 37 1C and pH 7.4, PE (5 Â 10À6 M), and the tissues were exposed and gassed continuously with 95% O2/5% CO2. to higenamine for 10 min. Then, the tissues were When the initial tension of each section was frozen rapidly in liquid nitrogen and homogenized maintained at approximately 2 g, the KH solution in ice-cold 6% trichloroacetic acid. The homoge- was changed approximately every 30 min (total nized tissues were centrifuged for 15 min, and equilibration period: 2 h) and allowed to reach cellular proteins in the supernatant were separated a stable condition. Once a stable condition was by conventional methods. Samples were divided reached, phenylephrine (PE) was added and into a normal CC group and groups of 10À7,10À6 and À5 the contraction level was observed. Each section 10 M according to the concentration of higen- was progressively stretched to the optimal point amine, and the concentrations of released cGMP on its length-tension curve as determined by the (n ¼ 8/group) and cAMP (n ¼ 8/group) were active tension developed to PE. Afterwards, a stable measured by immunoassay. The immunoassay was International Journal of Impotence Research Mechanism of action of higenamine on penile erection SC Kam et al 79 based on the competitive binding technique in Combined effects of higenamine and the PDE-5 which cGMP and cAMP present in a sample inhibitors on the CC compete with a fixed amount of horseradish perox- The relaxation effects of the PDE5 inhibitor on À6 idase-labeled cGMP and cAMP for sites on a precontracted CC strips with PE (5 Â 10 M) were rabbit polyclonal antibody.
Load more

Recommended publications
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • CAS Number Index
    2334 CAS Number Index CAS # Page Name CAS # Page Name CAS # Page Name 50-00-0 905 Formaldehyde 56-81-5 967 Glycerol 61-90-5 1135 Leucine 50-02-2 596 Dexamethasone 56-85-9 963 Glutamine 62-44-2 1640 Phenacetin 50-06-6 1654 Phenobarbital 57-00-1 514 Creatine 62-46-4 1166 α-Lipoic acid 50-11-3 1288 Metharbital 57-22-7 2229 Vincristine 62-53-3 131 Aniline 50-12-4 1245 Mephenytoin 57-24-9 1950 Strychnine 62-73-7 626 Dichlorvos 50-23-7 1017 Hydrocortisone 57-27-2 1428 Morphine 63-05-8 127 Androstenedione 50-24-8 1739 Prednisolone 57-41-0 1672 Phenytoin 63-25-2 335 Carbaryl 50-29-3 569 DDT 57-42-1 1239 Meperidine 63-75-2 142 Arecoline 50-33-9 1666 Phenylbutazone 57-43-2 108 Amobarbital 64-04-0 1648 Phenethylamine 50-34-0 1770 Propantheline bromide 57-44-3 191 Barbital 64-13-1 1308 p-Methoxyamphetamine 50-35-1 2054 Thalidomide 57-47-6 1683 Physostigmine 64-17-5 784 Ethanol 50-36-2 497 Cocaine 57-53-4 1249 Meprobamate 64-18-6 909 Formic acid 50-37-3 1197 Lysergic acid diethylamide 57-55-6 1782 Propylene glycol 64-77-7 2104 Tolbutamide 50-44-2 1253 6-Mercaptopurine 57-66-9 1751 Probenecid 64-86-8 506 Colchicine 50-47-5 589 Desipramine 57-74-9 398 Chlordane 65-23-6 1802 Pyridoxine 50-48-6 103 Amitriptyline 57-92-1 1947 Streptomycin 65-29-2 931 Gallamine 50-49-7 1053 Imipramine 57-94-3 2179 Tubocurarine chloride 65-45-2 1888 Salicylamide 50-52-2 2071 Thioridazine 57-96-5 1966 Sulfinpyrazone 65-49-6 98 p-Aminosalicylic acid 50-53-3 426 Chlorpromazine 58-00-4 138 Apomorphine 66-76-2 632 Dicumarol 50-55-5 1841 Reserpine 58-05-9 1136 Leucovorin 66-79-5
    [Show full text]
  • The Stimulant Higenamine in Weight Loss and Sports Supplements
    Clinical Toxicology ISSN: 1556-3650 (Print) 1556-9519 (Online) Journal homepage: http://www.tandfonline.com/loi/ictx20 The stimulant higenamine in weight loss and sports supplements Pieter A. Cohen, John C. Travis, Peter H. J. Keizers, Frederick E. Boyer & Bastiaan J. Venhuis To cite this article: Pieter A. Cohen, John C. Travis, Peter H. J. Keizers, Frederick E. Boyer & Bastiaan J. Venhuis (2018): The stimulant higenamine in weight loss and sports supplements, Clinical Toxicology, DOI: 10.1080/15563650.2018.1497171 To link to this article: https://doi.org/10.1080/15563650.2018.1497171 View supplementary material Published online: 06 Sep 2018. Submit your article to this journal Article views: 4561 View Crossmark data Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ictx20 CLINICAL TOXICOLOGY https://doi.org/10.1080/15563650.2018.1497171 RESEARCH ARTICLE The stimulant higenamine in weight loss and sports supplements Pieter A. Cohena, John C. Travisb, Peter H. J. Keizersc, Frederick E. Boyerb and Bastiaan J. Venhuisc aDepartment of Internal Medicine, Harvard Medical School, Boston, MA, USA; bNSF International, Ann Arbor, MI, USA; cNational Institute for Public Health and the Environment (RIVM), Bilthoven, Netherlands ABSTRACT ARTICLE HISTORY Background: Higenamine is a stimulant with cardiovascular properties recently prohibited in sport by Received 5 June 2018 the World Anti-Doping Agency (WADA). Higenamine is also a natural constituent of several traditional Revised 27 June 2018 botanical remedies and is listed as an ingredient in weight loss and sports supplements sold over-the- Accepted 1 July 2018 counter in the United States.
    [Show full text]
  • Ability of Higenamine and Related Compounds to Enhance Glucose Uptake in L6 Cells ⇑ Eisuke Kato , Shunsuke Kimura, Jun Kawabata
    Bioorganic & Medicinal Chemistry 25 (2017) 6412–6416 Contents lists available at ScienceDirect Bioorganic & Medicinal Chemistry journal homepage: www.elsevier.com/locate/bmc Ability of higenamine and related compounds to enhance glucose uptake in L6 cells ⇑ Eisuke Kato , Shunsuke Kimura, Jun Kawabata Laboratory of Food Biochemistry, Division of Applied Bioscience, Graduate School of Agriculture, Hokkaido University, Kita-ku, Sapporo, Hokkaido 060-8589, Japan article info abstract Article history: b2-Adrenergic receptor (b2AR) agonists are employed as bronchodilators to treat pulmonary disorders, Received 13 September 2017 but are attracting attention for their modulation of glucose handling and energy expenditure. Revised 2 October 2017 Higenamine is a tetrahydroisoquinoline present in several plant species and has b2AR agonist activity, Accepted 13 October 2017 but the involvement of each functional groups in b2AR agonist activity and its effectiveness compared Available online 14 October 2017 with endogenous catecholamines (dopamine, epinephrine, and norepinephrine) has rarely been studied. Glucose uptake of muscle cells are known to be induced through b2AR activation. Here, the ability to Keywords: enhance glucose uptake of higenamine was compared with that of several methylated derivatives of hige- b2-Adrenergic receptor namine or endogenous catecholamines. We found that: (i) the functional groups of higenamine except for Tetrahydroisoquinoline 0 Glucose uptake the 4 -hydroxy group are required to enhance glucose uptake; (ii) higenamine shows a comparable ability Muscle cell to enhance glucose uptake with that of epinephrine and norepinephrine; (iii) the S-isomer shows a Diabetes greater ability to enhance glucose uptake compared with that of the R-isomer. Ó 2017 Elsevier Ltd. All rights reserved.
    [Show full text]
  • On Cardiovascular System Are Re- Periments on the Heart of Toads, Frogs, Guinea Pigs and Rabbits in Vitro, and Showed a Cardiotonic Effect of Aco- Viewed
    Online Submissions:http://www.journaltcm.com J Tradit Chin Med 2012 September 15; 32(3): 1-2 [email protected] ISSN 0255-2922 © 2012 JTCM. All rights reserved. REVIEW Pharmacological effects of Chinese herb aconite (Fuzi) on cardiovas- cular system Dandan Zhao, Jie Wang, Yanjing Cui, Xinfang Wu aa Dandan Zhao, Jie Wang, Yanjing Cui, Xinfang Wu, (Ranunculaceae). Fuzi tastes spicy and sweet, has a hot Guang'anmen Hospital, China Academy of Chinese Medical nature and toxicity, acts on the heart, kidney and Sciences, Beijing 100053, China spleen meridians and plays a role in saving yang for the Dandan Zhao, Beijing University of Traditional Chinese treatment of collapse, supplementing kidney yang, and Medicine, Beijing 100029, China eliminating cold to stop pain. Fuzi (aconite) consists of Supported by the Capital Medical Science and Technology a variety of alkaloids, such as the diester-diterpene alka- Development Program (No. SF-2007-I-04) loids, aconitine, hypaconitine, mesaconitine, and hige- Correspondence to: Prof. Jie Wang, Guang'anmen Hospi- namine. Aconite also is composed of some lipids, such tal, China Academy of Chinese Medical Sciences, Beijing as fatty acids, phosphatidate calcium, and steroids. It is 100053, China. [email protected] mainly clinically used for treatment of heart failure, Telephone: +86-10-88001381 shock and hypotension subsequent to acute myocardial Accepted: , March 1, 2012 infarction, coronary heart disease and rheumatic heart disease. Along with the repeated application of aconite in clinical practice and studies on pharmacology, its use in the cardiovascular system has been the focus of in- Abstract creasing research. In this article, aconite's pharmacolog- ical effects on the cardiovascular system are summa- Fuzi (aconite, Radix Aconiti praeparata), a widely rized.
    [Show full text]
  • A Chemoinformatics Approach for the in Silico Identification of Interactions Between Psychiatric Drugs and Plant-Based Food
    Diploma Thesis A Chemoinformatics Approach for the In Silico Identification of Interactions Between Psychiatric Drugs and Plant-Based Food Anna Maria Tsakiroglou Thesis Supervisors: Assoc. Prof.: Kouskoumvekaki Irene Assoc. Prof.: Topakas Evangelos February 2016 Dedication To all the people who made the realization of this work possible. My supervisor for the most useful input and advice along the way. My parents for their unending support. To Katerina, and last, but not least, to Panagiotis, for always being there for me, even from so far away. You are awesome. i ii Abstract The overall objective of this project was the development of a systematic approach for identifying potential interactions between plant-based food and marketed psycholeptics and psychoanaleptic drugs. The problem was addressed, initially, by pairing psychiatric agents and phytochemicals to their common protein targets, using information available in online databases, such as NutriChem 1.0 [21] and Drugbank [16] and constructing the food-drug interaction networks. Thereupon, a search for additional phytochemicals that would be expected to interact with targets of psychiatric drugs was carried out. More specifically, three protein targets, P07550, P28222 and P14416 were selected, based on their frequency of interaction with both psycholeptics and psychoanaleptics and the avail- ability of 3D structural information in PDB [19]. For these protein targets, ligand-based pharmacophoric hypothesis were generated, using experimental activity data from the literature, and the HypoGen feature of Accelrys Discovery Studio (DS) [7]. The phar- macophore models were validated using external test sets and Fisher’s method. Sub- sequently, the models were used as queries to screen the NutriChem 1.0 database for more potentially active phytochemicals.
    [Show full text]
  • 2019-20 NCAA Banned Substances It Is the Student-Athlete's
    2019-20 NCAA Banned Substances It is the student-athlete’s responsibility to check with the appropriate or designated athletics staff before using any substance. The NCAA bans the following drug classes. a. Stimulants b. Anabolic agents c. Alcohol and beta blockers (banned for rifle only) d. Diuretics and masking agents e. Narcotics f. Cannabinoids g. Peptide hormones, growth factors, related substances and mimetics h. Hormone and metabolic modulators (anti-estrogens) i. Beta-2 agonists Note: Any substance chemically/pharmacologically related to all classes listed above and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g., drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is also banned. The institution and the student-athlete shall be held accountable for all drugs within the banned-drug class regardless of whether they have been specifically identified. Examples of substances under each class can be found at www.ncaa.org/drugtesting. There is no complete list of banned substances. Substances and Methods Subject to Restrictions: • Blood and gene doping. • Local anesthetics (permitted under some conditions). • Manipulation of urine samples. • Beta-2 agonists (permitted only by inhalation with prescription). • Tampering of urine samples. NCAA Nutritional/Dietary Supplements: Warning: Before consuming any nutritional/dietary supplement product, review the product and its label with your athletics department staff! • Nutritional/Dietary supplements, including vitamins and minerals, are not well regulated and may cause a positive drug test. • Student-athletes have tested positive and lost their eligibility using nutritional/dietary supplements. • Many nutritional/dietary supplements are contaminated with banned substances not listed on the label.
    [Show full text]
  • NJSIAA Banned Drug List 2018-19
    2018-19 NJSIAA Banned Drugs IT IS YOUR RESPONSIBILITY TO CHECK WITH THE APPROPRIATE OR DESIGNATED ATHLETICS STAFF BEFORE USING ANY SUBSTANCE The NJSIAA bans the following classes of drugs: Stimulants Anabolic Agents Alcohol and Beta Blockers Diuretics and Other Masking Agents Street Drugs Peptide Hormones and Analogues Anti-estrogens Beta-2 Agonists Note: Any substance chemically related to these classes is also banned. THE INSTITUTION AND THE STUDENT-ATHLETE SHALL BE HELD ACCOUNTABLE FOR ALL DRUGS WITHIN THE BANNED DRUG CLASS REGARDLESS OF WHETHER THEY HAVE BEEN SPECIFICALLY IDENTIFIED. Drugs and Procedures Subject to Restrictions Blood Doping Gene Doping Local Anesthetics (under some conditions) Manipulation of Urine Samples Beta-2 Agonists permitted only by prescription and inhalation NJSIAA Nutritional/Dietary Supplements Warning Before consuming any nutritional/dietary supplement product, review the product with the appropriate or designated athletics department staff! Dietary supplements, including vitamins and minerals, are not well regulated and may cause a positive drug test result. Student-athletes have tested positive and lost their eligibility using dietary supplements. Many dietary supplements are contaminated with banned drugs not listed on the label. Any product containing a dietary supplement ingredient is taken at your own risk. NOTE TO STUDENT-ATHLETES: THERE IS NO COMPLETE LIST OF BANNED SUBSTANCES. DO NOT RELY ON THIS LIST TO RULE OUT ANY SUPPLEMENT INGREDIENT. CHECK WITH YOUR ATHLETICS DEPARTMENT STAFF PRIOR TO USING A SUPPLEMENT. REMINDER: ANY DIETARY SUPPLEMENT INGREDIENT IS TAKEN AT THE STUDENT’S OWN RISK. Some Examples of NJSIAA Banned Substances in Each Drug Class Do NOT RELY ON THIS LIST TO RULE OUT ANY LABEL INGREDIENT.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0184806 A1 Barlow Et Al
    US 20100184806A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0184806 A1 Barlow et al. (43) Pub. Date: Jul. 22, 2010 (54) MODULATION OF NEUROGENESIS BY PPAR (60) Provisional application No. 60/826,206, filed on Sep. AGENTS 19, 2006. (75) Inventors: Carrolee Barlow, Del Mar, CA (US); Todd Carter, San Diego, CA Publication Classification (US); Andrew Morse, San Diego, (51) Int. Cl. CA (US); Kai Treuner, San Diego, A6II 3/4433 (2006.01) CA (US); Kym Lorrain, San A6II 3/4439 (2006.01) Diego, CA (US) A6IP 25/00 (2006.01) A6IP 25/28 (2006.01) Correspondence Address: A6IP 25/18 (2006.01) SUGHRUE MION, PLLC A6IP 25/22 (2006.01) 2100 PENNSYLVANIA AVENUE, N.W., SUITE 8OO (52) U.S. Cl. ......................................... 514/337; 514/342 WASHINGTON, DC 20037 (US) (57) ABSTRACT (73) Assignee: BrainCells, Inc., San Diego, CA (US) The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system (21) Appl. No.: 12/690,915 including by stimulating or increasing neurogenesis, neuro proliferation, and/or neurodifferentiation. The disclosure (22) Filed: Jan. 20, 2010 includes compositions and methods based on use of a peroxi some proliferator-activated receptor (PPAR) agent, option Related U.S. Application Data ally in combination with one or more neurogenic agents, to (63) Continuation-in-part of application No. 1 1/857,221, stimulate or increase a neurogenic response and/or to treat a filed on Sep. 18, 2007. nervous system disease or disorder. Patent Application Publication Jul. 22, 2010 Sheet 1 of 9 US 2010/O184806 A1 Figure 1: Human Neurogenesis Assay Ciprofibrate Neuronal Differentiation (TUJ1) 100 8090 Ciprofibrates 10-8.5 10-8.0 10-7.5 10-7.0 10-6.5 10-6.0 10-5.5 10-5.0 10-4.5 Conc(M) Patent Application Publication Jul.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0058896 A1 Dietrich Et Al
    US 200400.58896A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0058896 A1 Dietrich et al. (43) Pub. Date: Mar. 25, 2004 (54) PHARMACEUTICAL PREPARATION (30) Foreign Application Priority Data COMPRISING AN ACTIVE DISPERSED ON A MATRIX Dec. 7, 2000 (EP)........................................ OO126847.3 (76) Inventors: Rango Dietrich, Konstanz (DE); Publication Classification Rudolf Linder, Kontanz (DE); Hartmut Ney, Konstanz (DE) (51) Int. Cl." ...................... A61K 31156; A61K 31/4439 (52) U.S. Cl. ........................... 514/171; 514/179; 514/338 Correspondence Address: (57) ABSTRACT NATH & ASSOCATES PLLC 1030 FIFTEENTH STREET, N.W. The present invention relates to the field of pharmaceutical SIXTH FLOOR technology and describes a novel advantageous preparation WASHINGTON, DC 20005 (US) for an active ingredient. The novel preparation is Suitable for 9 producing a large number of pharmaceutical dosage forms. (21) Appl. No.: 10/433,398 In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix com (22) PCT Filed: Dec. 6, 2001 posed of one or more excipients Selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid (86) PCT No.: PCT/EPO1/14307 eSter. US 2004/0058896 A1 Mar. 25, 2004 PHARMACEUTICAL PREPARATION 0008 Further subject matters are evident from the claims. COMPRISING AN ACTIVE DISPERSED ON A MATRIX 0009. The preparations for the purpose of the invention preferably comprise numerous individual units in which at least one active ingredient particle, preferably a large num TECHNICAL FIELD ber of active ingredient particles, is present in an excipient 0001. The present invention relates to the field of phar matrix composed of the excipients of the invention (also maceutical technology and describes a novel advantageous referred to as active ingredient units hereinafter).
    [Show full text]
  • The Iditarod Trail Committee Exists to Preserve the Tradition of Dog Mushing in Alaska by Staging the World Premier Sled Dog Race Along the Iditarod Trail
    1/1/2022 IDITAROD TRAIL CANINE DRUG TESTING MANUAL COMMITTEE The Iditarod Trail Committee exists to preserve the tradition of dog mushing in Alaska by staging the world premier sled dog race along the Iditarod Trail. 0 TABLE OF CONTENTS CANINE DRUG TESTING OVERVIEW………………………………………..........2 DRUG TESTING VIOLATION PREVENTION MEASURES…………………....5 CHAIN OF CUSTODY (EVIDENCE) PROTOCOLS..................………………7 GUIDELINES FOR PERFORMANCE ENHANCING SUBSTANCES………….9 ALPHABETICAL LIST OF PROHIBITED SUBSTANCES………………………..14 LABORATORY TEST RESULTS…...…………………………………………………...47 PROTOCOLS FOR A POTENTIAL DRUG TESTING VIOLATION………… 49 DRUG TESTING VIOLATION APPEAL AND HEARING PROCESS……....51 1 CANINE DRUG TESTING OVERVIEW In its mission of testing for the presence of performance enhancing medications, the Iditarod Canine Drug Testing Program has two primary purposes. The first is to protect the health of the dogs from the use of unauthorized medications. The second is to establish a “level playing field” so that all contestants have equal opportunity and are exhibiting innate skills and endurance. For these reasons, drug testing is a high priority for the ITC. Canine drug testing in a long-distance sled dog race creates unique challenges when compared to human, equine, Greyhound and even many other types of sled dog competition. Because of the extremely high caloric intake over a period of 9-14 days, large volumes of commercial dog food and raw meats, neither of which are typically graded for human consumption and may in fact have 4-D (Diseased, Down, Dying or Dead) livestock components, are consumed by an Iditarod dog. This creates a high probability of exposure to large (farm) animal pharmaceuticals through ingestion, which are often detected at trace levels in urine.
    [Show full text]
  • Rana Dadashova
    University of Alberta Is Atomoxetine effective in treating nicotine withdrawal? A double-blind, placebo-controlled, fixed-dose study by Rana Dadashova A thesis submitted to the Faculty of Graduate Studies and Research in partial fulfillment of the requirements for the degree of Master of Science Department of Psychiatry ©Rana Dadashova Fall 2011 Edmonton, Alberta Permission is hereby granted to the University of Alberta Libraries to reproduce single copies of this thesis and to lend or sell such copies for private, scholarly or scientific research purposes only. Where the thesis is converted to, or otherwise made available in digital form, the University of Alberta will advise potential users of the thesis of these terms. The author reserves all other publication and other rights in association with the copyright in the thesis and, except as herein before provided, neither the thesis nor any substantial portion thereof may be printed or otherwise reproduced in any material form whatsoever without the author's prior written permission. Dedication This work is dedicated to my lovely husband Mehti Dadashov and my dear children Seymur and Kamilla, whose love, inspiration and great support made this project successful. I also dedicate these theses to my dear parents Vera Stadnik and Valeriy Stadnik, whose deepest love and couching has been navigating me throughout my life. Abstract Drugs that affect noradrenaline neurotransmission are used as therapy for smoking cessation. A recent study in individuals with attention-deficit and hyperactivity disorder (ADHD) suggested that atomoxetine, a noradrenaline reuptake inhibitor, may reduce cravings in individuals with ADHD who also smoked. The present double-blind, placebo-controlled, fixed-dose study investigated the effect of atomoxetine on nicotine withdrawal in otherwise healthy smokers, who has no psychiatric condition, and wish to stop smoking.
    [Show full text]